Contact this trialFirst, we need to learn more about you.
Proteasome Inhibitor
Daratumumab + KRd for Multiple Myeloma
Recruiting1 awardPhase 2
Charlotte, North Carolina
This trial is testing a new combination of drugs to treat Multiple Myeloma, which is a cancer of the plasma cells. The drugs work together to attack the cancer cells and destroy them. This new combination has shown to be effective in subjects with MM in preliminary trials.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service